By Adriano Marchese

Elanco Animal Health laid out its growth targets for 2026, in line with its three-year plan, after fourth-quarter revenue and adjusted earnings topped expectations.

The animal health company on Tuesday said it expects revenue to grow to $4.95 billion to $5.02 billion, which is 4% to 6% organic growth on a constant currency basis. The company said it is raising its innovation revenue target to $1.15 billion.

Analysts expected revenue for the year to be $4.93 billion, according to FactSet.

Adjusted earnings before interest, taxes, depreciation and amortization is expected to be between $955 million and $985 million, with analysts expecting $977 million for the year.

Adjusted earnings are forecast to be between $1.00 and $1.06 a share while analysts expected $1.03 a share.

Elanco said the guidance is in line with its three-year outlook introduced at its investor day in December.

For its fourth quarter, Elanco posted a net loss of $276 million, or 56 cents a share, widening from a loss of $8 million, or 2 cents a share, in the same quarter a year ago.

Adjusted earnings were 13 cents a share, beating the top end of its own guidance, which was set to a range of 9 cents to 12 cents. It was also higher than analyst expectations, which projected 11 cents a share.

Revenue rose 12% to $1.14 billion, coming in ahead of analyst expectations of $1.09 billion for the quarter.

Chief Executive Jeff Simmons credits the year's performance to growth across all its business units, with contributions from price and volume, and most of its largest markets growing.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

February 24, 2026 07:00 ET (12:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.